Oric Pharmaceuticals, Inc. (ORIC)
ORIC moved a median of +0.22% 30 minutes after news, and -0.52% by the close. How ORIC actually reacts to news — the realized, point-in-time move the market made, measured across 337 labeled events over the last three years with zero look-ahead.
ORIC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.14% | 53% | 337 |
| 30-min | +0.22% | 53% | 337 |
| 60-min | -0.37% | 45% | 337 |
| to close | -0.52% | 45% | 335 |
| Middle 50% of ORIC reactions | -1.72% to +1.32% |
|---|---|
| Median reaction (30-min) | +0.22% |
| Measured reactions | 337 |
Half of all Oric Pharmaceuticals, Inc. news events land between -1.72% and +1.32% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ORIC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 28 | -1.92% | 18% | -0.71% |
| Rating reiterations | 100 | 0.00% | 49% | +0.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ORIC ranks against every other measured name →
That’s how ORIC usually reacts — get an email when it moves on news →Email me when ORIC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ORIC's baseline. Nothing else.
Recent ORIC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development | Press release | GlobeNewswire | -2.46% | -4.92% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.63% | -1.26% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.16% | -0.40% | |
| ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.44% | -3.27% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.59% | — | |
| Form 10-Q Oric Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.40% | +26.60% | |
| Form 8-K Oric Pharmaceuticals, For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +2.40% | +26.60% | |
| ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates | Press release | GlobeNewswire | +2.40% | +26.60% | |
| Form 8-K Oric Pharmaceuticals, For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -5.14% | |
| Form S-8 Oric Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -0.17% | -5.14% | |
| ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 | Press release | GlobeNewswire | +1.82% | -2.71% | |
| ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer | Press release | GlobeNewswire | +0.62% | +6.09% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.29% | -6.27% | |
| Form 8-K Oric Pharmaceuticals, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.78% | -0.45% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.39% | -1.31% | |
| ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.06% | -1.74% | |
| Form 10-Q Oric Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.42% | +1.70% | |
| Form 8-K Oric Pharmaceuticals, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | +1.70% | |
| ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates | Press release | GlobeNewswire | +0.42% | +1.70% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.05% | -2.50% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.96% | -0.72% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.10% | +2.28% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.10% | -4.64% | |
| Form ARS Oric Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.74% | -0.74% | |
| Form DEF 14A Oric Pharmaceuticals, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | -0.74% | -0.74% | |
| Form DEFA14A Oric Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.74% | -0.74% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +2.77% | +0.99% | |
| ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.32% | -4.00% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.23% | -2.75% | |
| ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.69% | -0.32% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.23% | +1.59% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.64% | -1.65% | |
| ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting | Press release | GlobeNewswire | +0.23% | +1.59% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.90% | +0.00% | |
| Form 8-K Oric Pharmaceuticals, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +3.87% | -26.06% | |
| ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile | Press release | GlobeNewswire | +3.87% | -26.06% | |
| ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC | Press release | GlobeNewswire | +1.65% | -0.58% | |
| ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting | Press release | GlobeNewswire | -0.17% | -8.97% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.75% | -2.92% | |
| Form 10-K Oric Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.41% | +11.09% | |
| Form 8-K Oric Pharmaceuticals, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | +11.09% | |
| Form S-8 Oric Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -0.41% | +11.09% | |
| ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates | Press release | GlobeNewswire | -0.41% | +11.09% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.26% | +3.48% | |
| ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.63% | -0.10% | |
| ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones | Press release | GlobeNewswire | -3.19% | +0.66% | |
| ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.18% | +2.00% | |
| Form 8-K Oric Pharmaceuticals, For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | -5.45% | -15.64% | |
| ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -5.45% | -15.64% | |
| ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 | Press release | GlobeNewswire | +1.11% | -5.66% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ORIC section they belong to.
Where else ORIC is measured.
ORIC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oric Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ORIC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 337 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of ORIC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ORIC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.